Adjuvant Capecitabine and Oxaliplatin vs. Capecitabine and Paclitaxel in Gastric Cancer Patients after D2 Gastrectomy
Jing Sun(Chongqing Academy of Animal Science), Xiaofeng Chen(Jiangsu Cancer Hospital), Yanhong Gu(Nanjing Medical University), Oluf Dimitri Røe(Norwegian University of Science and Technology), Yongqian Shu(Jiangsu Province Hospital), Peinan Lin, Chong Liu(Guangxi Medical University), Xiao Li(Shanghai Jiao Tong University), Ping Li(Fujian Medical University), Xiaomin Cai(Fujian Normal University), Shaohua He(Huaihua University), Yiqian liu, Lele Li(Nantong University), Jing Qian(University of Massachusetts Amherst)
Cited by 0
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475